NCT05928806 - Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

October 10, 2025

Study Completion Date

October 12, 2026

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG

Botensilimab

Botensilimab 75mg IV

DRUG

Balstilimab

Balstilimab 450mg IV

DRUG

Ipilimumab

Ipilimumab 1mg/kg IV

DRUG

Nivolumab

Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV

Trial Locations (13)

10032

RECRUITING

Columbia University Irving Medical Center, New York

14850

RECRUITING

Cornell University, Ithaca

19104

RECRUITING

Penn Medicine Abramson Cancer Center, Philadelphia

20057

RECRUITING

Georgetown University, Washington D.C.

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

92093

RECRUITING

University of California San Diego, La Jolla

06520

RECRUITING

Yale University, Yale Cancer Center, New Haven

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber - Partners Cancer Care, Inc, Boston

07601

RECRUITING

John Theurer Cancer Center, Hackensack